Other Studies
Search through ClinicalTrials.gov This site, produced by the U.S. National Library of Medicine (NLM), provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.
Prevention and Surveillance Studies
- Breast cancer surveillance trials
- Breast cancer prevention trials
- Ovarian cancer surveillance trials
- Ovarian cancer prevention trials
- Pancreatic cancer surveillance trials
- Prostate cancer surveillance trials
- Prostate cancer prevention trials
PARP Inhibitor Studies or Hereditary Cancer-Specific Treatment Studies
PARP Inhibitors are medications that may specifically target BRCA-associated cancers. Phase I and Phase II PARP Inhibitor studies are now enrolling patients at sites throughout the US and Europe. Below are links to information on PARP Inhibitor studies.
- PARP Inhibitor breast cancer studies on clinicaltrials.gov
- PARP Inhibitor ovarian cancer studies on clinicaltrials.gov
- PARP Inhibitor pancreatic cancer studies on clinicaltrials.gov
- PARP Inhibitor prostate cancer studies on clinicaltrials.gov
- PARP Inhibitor melanoma studies on clinicaltrials.gov
You can also call the following contacts at the institutions below regarding PARP Inhibitor clinical trials for breast cancer:
- Stanford PARP Inhibitor breast cancer study for women with triple-negative, newly diagnosed breast cancer; Meredith Mills Project Manager, (650) 724-5223 or email bluett@stanford.edu
A new Phase III clinical trial using PARP Inhibitors in combination with chemotherapy just opened at multiple sites across the United States for women with advanced (stage IV) breast cancer. The agent BSI-201 is one of the agents used for the Phase II study which reported positive results at ASCO. The study is open in 66 sites across the country. For more information on enrollment criteria contact BiPar Sciences at (866) 668-2232 or email clinicaltrials@BiParSciences.com.
Treatment studies for "triple-negative" breast cancer
"Triple-negative" breast cancer refers to a type of breast cancer that is particularly common in women with BRCA1 mutations. These cancers are estrogen- and progesterone-receptor negative, and also negative for overexpression of Her2neu. Approximately 85% of BRCA1 breast cancers are "triple-negative." Researchers are studying whether certain treatments may work particularly well for "triple-negative" cancers. Below are links to studies for triple-negative breast cancers.
A new Phase III clinical trial for triple-negative breast cancer using PARP Inhibitors in combination with chemotherapy just opened at multiple sites across the United States for women with advanced (stage IV) breast cancer. The agent BSI-201 is one of the agents used for the Phase II study which reported positive results at ASCO. The study is open in 66 sites across the country. For more information on enrollment criteria contact BiPar Sciences at (866) 668-2232 or email clinicaltrials@BiParSciences.com.
Other treatment studies
Other detection or prevention studies
The following sections of the FORCE website list research studies which may not be not listed on ClinicalTrials.gov:
- Breast cancer chemoprevention studies
- Ovarian cancer chemoprevention studies
- Breast cancer surveillance studies
- Ovarian cancer surveillance studies
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.